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Abstract
Background: Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic
disorders (PNDs) who are under the care of general practitioners (GPs) in the UK are not well understood.
Methods: Using a large electronic UK database, we identified all adults (age ≥ 18 years) with any GP encounters
between 1 January 2006 - 31 December 2006 at which a diagnosis of PND was noted ("PND patients”). An age-and
gender-matched comparison group also was constituted consisting of randomly selected patients with one or
more GP encounters-but no mention of PNDs-during this period. Characteristics and patterns of healthcare
utilization of patients in the two groups were then examined over the one-year study period.
Results: The study sample consisted of 31,688 patients with mention of PNDs and an equal number of matched
comparators; mean age was 56 years, and 62% were women. The prevalence of various comorbidities was higher
among patients in the PND group, including digestive disorders (31% vs. 17% for comparison group), circulatory
disorders (29% vs. 22%), and depression (4% vs. 3%) (all p < 0.01). Receipt of prescriptions for pain-related
pharmacotherapy also was higher among PND patients, including nonsteroidal anti-inflammatory drugs (56% of PND
patients had one or more such prescriptions vs. only 22% in the comparison group), opioids (49% vs. 12%), tricyclic
antidepressants (20% vs. 1%), and antiepileptics (12% vs. 1%) (all p < 0.01). PND patients also averaged significantly
more GP visits (22.8 vs. 14.2) and referrals to specialists (2.8 vs. 1.4) over one year (both comparisons p < 0.01).
Conclusions: Patients with PNDs under the care of GPs in the UK have relatively high levels of use of healthcare
services and pain-related pharmacotherapy.
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Background
Neuropathic pain results from dysfunction of either the
peripheral nerves or, less commonly, the central nervous
system [1,2]. Neuropathic painc a nb ed i f f i c u l tt ot r e a t ,
and often requires the use of antiepileptic drugs (AEDs)
and/or tricyclic antidepressants (TCAs) instead of–or in
addition to–agents that are often used to treat nocicep-
tive pain, such as nonsteroidal anti-inflammatory drugs
(NSAIDs) and opioids. Previous guidelines for the treat-
ment of painful neuropathies recommended a stepwise
approach to treatment, with TCAs and/or AEDs used
initially, followed by other agents (e.g., duloxetine,
opioids) as needed. Pain clinics and/or psychological
support also were recommended for patients whose pain
remained inadequately controlled following multiple
trials with different drugs [3,4]. Currently, TCAs,
selected AEDs (i.e., gabapentin, pregabalin, carbamaze-
pine), serotonin-norepinephrine reuptake inhibitor
(SNRI) antidepressants (i.e., duloxetine, venlafaxine), and
topical lidocaine are all recommended as first- and/or
second-line therapy for pharmacologic management of
painful neuropathies; tramadol and opioids are now
recommended as second- and/or third-line therapy [5,6].
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etiology, pathophysiology, and treatment of neuropathic
pain, relatively little has been reported about the clinical
characteristics and costs of patients with painful neuro-
pathic disorders (PNDs) in clinical practice, including
their levels of use of pain-related pharmacotherapy and
healthcare services. These issues were examined by the
authors in two prior studies in which patients with
PNDs were compared with an equal number of age-and
sex-matched comparators [7,8]. In the first study, 55,686
patients with PNDs in the US were identified during
calendar-year (CY) 2000. In the second study, 275,685
patients with PNDs who were seen by general practi-
tioners (GPs) in Germany between 1 August 2005 and
31 July 2006 were identified. In both studies, the preva-
lence of various comorbidities–including fibromyalgia,
osteoarthritis, and depression–was much higher in
patients with PNDs, as was the use of a range of pain-
related medications, including opioids, AEDs, antide-
pressants, and benzodiazepines. Patients with PNDs
received NSAIDs and opioids to a much greater extent
than one would expect if treatment guidelines relevant
for the time period of either study had been followed.
Lachaine and colleagues used similar methods to exam-
ine the burden of PNDs among patients in Quebec [9].
Similar to findings reported for patients in the US and
Germany, patients with PNDs (n = 4912) were reported
to be more likely than their age- and gender-matched
comparators to have comorbidities; they also had higher
levels of use of pain-related medications, such as AEDs,
antidepressants, opioids, and NSAIDs [9].
There is some evidence that patients with PNDs in the
UK are similarly treated. In their study of approximately
25,000 patients with post-herpetic neuralgia, trigeminal
neuralgia, phantom limb pain, or painful diabetic neuro-
p a t h yn e w l yd i a g n o s e db yaG Pi nt h eU Kb e t w e e n
CY1992 and CY2002, Hall et al. reported that the medi-
cations most commonly prescribed were amitriptyline,
carbamazepine, coproxamol, codydramadol, and codeine
+ paracetamol [10]. In a second study that also focused
on patients with these four PNDs in a UK GP database
between May 2002 and July 2005, Hall et al. found that
the most commonly prescribed drugs included TCAs,
AEDs, and opioids [11]. A study by Gore and colleagues
identified 30,999 patients with PNDs in a UK GP data-
base in CY2001 (16,690 with pain predominantly neuro-
pathic in nature ["pure"], and 14,309 with pain likely to
have both nociceptive and neuropathic components
["mixed"]) [12]. Use of medications with proven efficacy
in neuropathic pain (e.g., AEDs, TCAs) was reported to
be low, although levels of use were higher in patients
with “pure” versus “mixed” neuropathic pain. Many
PND patients also had been prescribed agents that have
not typically demonstrated efficacy in neuropathic pain
(e.g., NSAIDs).
While providing important insights into the treatment
of PNDs in the UK, these studies are not without their
limitations. The two studies by Hall and colleagues were
limited to the four above-noted PNDs; the degree to
which their findings are generalizeable to the overall
population of patients with PNDs is unknown. More-
over, none of these studies compared healthcare utiliza-
tion and pharmacotherapy between patients with PNDs
versus those without these disorders. We address this
issue in the study described below, focusing attention
on patients under the care of GPs in the UK.
Methods
Data were obtained from The Health Improvement Net-
work (THIN) database, which consists of patient-level
information on GP encounters from approximately 300
computerized GP practices throughout the UK. All
practices registered with THIN use a clinical manage-
ment system provided by In Practice Systems Ltd.
(INPS). Many practices have contributed over 15 years
of data to THIN, and more than 5 million patients are
represented in the database. The database documents all
patient care by GPs, and includes extensive information
on diagnoses and treatments; it is designed to be repre-
sentative of GP practices throughout the UK. All patient
identifiers in the database are fully encrypted to protect
patient confidentiality.
Available information in the THIN database includes
date of service, diagnoses (in READ format), actions
taken (e.g., referrals to other providers [i.e., specialists]),
and medications prescribed–including the prescribing
date and the quantity prescribed. Selected demographic
information is also available, including patient age and
gender. All patient-level data can be arrayed chronologi-
cally to provide a detailed, longitudinal profile of all
medical and pharmacy services rendered by participating
GPs.
The study protocol was submitted for review to–and
subsequently approved by–the UK National Health Ser-
vice (NHS) Multi-Centre Research Ethics Committee
(MREC).
The study sample consisted of all patients, aged ≥ 18
years, with one or more visits to GPs between 1 January
2006 and 31 December 2006 ("study period”)( t h em o s t
recent one-year period for which data were available at
t h et i m eo fs t u d y )a tw h i c had i a g n o s i so fP N Dw a s
noted (Appendix). A comparison group also was consti-
tuted, consisting of patients who did not have any GP
encounters with noted diagnoses of PNDs during the
same period; they were randomly selected and matched
to PND patients based on age (within 1 year) and sex.
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painful disorders, however, such as osteoarthritis and
fibromyalgia.) All GP encounters were compiled for
PND patients and patients in the comparison group
over the 12-month study period.
The prevalence of selected clinically recognized
comorbidities (e.g., arthritis, diseases of the circulatory
system) was examined in both groups. Patients were
deemed to have any of the conditions of interest if
they had any encounters during the study period with
a corresponding diagnosis code, or a prescription for a
drug specific to that condition (e.g., diabetes was
defined based on presence of corresponding [READ]
diagnosis codes or prescriptions for any antidiabetic
drugs).
The number of patients receiving prescriptions for
pain-related and non-pain-related medications during
the study period was examined. Medications were desig-
nated as “painrelated” based on their classification as
analgesics or adjuvant medications in the World Health
Organization’s( W H O )“analgesic ladder” [13]. Although
the WHO ladder was developed originally for cancer
pain, the spectrum of pain-related medications also is
used for the treatment of neuropathic pain [7,8,14-34].
Pain-related medications were defined to include: (1)
AEDs; (2) benzodiazepines; (3) corticosteroids; (4) cyclo-
oxygenase (COX)-2 inhibitors and other prescription
NSAIDs; (5) muscle relaxants; (6) sedatives/hypnotics;
(7) opioids (both short- and long-acting); (8) antidepres-
sants (including TCAs, monoamine oxidase [MAO]
inhibitors, and selective serotonin reuptake inhibitors
[SSRIs]); (9) antimigraine agents; and (10) miscellaneous
agents (injectable agents [e.g., bupivacaine], topical
analgesics [e.g., lidocaine]). All other medications were
designated non-pain-related.
Use of healthcare services during the 12-month study
period was examined in terms of the numbers of GP
visits, referrals from GPs to other healthcare providers
(e.g., specialists), and hospitalizations; “sick notes” (phy-
sician-excused absences from work) also was examined.
We did not attempt to attribute care specifically to the
treatment of PNDs, because of inherent difficulties in
attribution using electronic healthcare databases. We
also did not attempt to examine nonpharmacologic
treatments for PNDs, such as spinal cord stimulation
and psychological support.
The statistical significance of differences in continuous
measures between the PND and comparison groups was
ascertained using paired t-tests or Wilcoxon signed-rank
tests, as appropriate. McNemar’sa n dB o w k e r ’st e s t s ,a s
appropriate, were used to ascertain the statistical signifi-
cance of differences in categorical measures. All analyses
were conducted using PC-SAS
® v.8.4 [35].
Results
We identified a total of 31,688 patients with one or
more encounters at which PNDs were recorded between
1 December 2006 and 31 January 2006; a comparison
group of the same size also was constituted, matched on
age and gender. The most frequently noted PNDs were
neuropathic back pain (46.4% of all PND patients),
nerve impingement syndromes (e.g., carpal tunnel syn-
drome) (14.1%), and unspecified neuropathic pain (e.g.,
“neuritis, unspecified”, “neuralgia unspecified”) (9.7%)
(Table 1).
Mean (SD) age of patients in both groups was 56.1
(16.6) years, and 61.6% were women (Table 2). Nearly
one-third of patients (32.9%) were ≥ 65 years of age.
The prevalence of various comorbidities was higher
among PND patients, including diseases of the respira-
tory system (33.1% vs. 24.6%, respectively), diseases of
the digestive system (31.5% vs. 17.3%), diseases of the
circulatory system (28.6% vs. 21.6%), depression (4.3%
v s .2 . 6 % ) ,a n da n x i e t y( 2 . 8 %v s .1 . 7 % )( a l lp < 0.01).
Approximately one in five PND patients (i.e., 23%) had
at least one encounter during the study period with a
diagnosis of “symptoms, signs, and ill-defined condi-
tions”, compared with only 11.1% of patients in the
comparison group (p < 0.01). Eighty-eight percent of
patients with PNDs had two or more comorbidities
noted by their GPs during the study period, versus
56.9% for the comparison group.
The number of patients who received prescriptions
from their GPs for pain-related pharmacotherapy was
approximately twice as high in the PND group than in
the comparison group (82.9% vs. 43.4%,, respectively; p
< 0.01), including “traditional” analgesics, such as
NSAIDs and opioids, as well as “adjuvant” medications,
such as AEDs, benzodiazepine, and tricyclic antidepres-
sants (Table 3). The pain-related medications most com-
monly prescribed by GPs to patients with PNDs
included NSAIDs (including COX-2 inhibitors) (56.5%
of PND patients vs. 22.3% in the comparison group),
opioids (49.5% vs. 13.8%), antidepressants (primarily
TCAs) (29.9% vs. 9.6%), benzodiazepines (13.0% vs.
4.9%), and AEDs (12.1% vs. 0.9%) (all p < 0.01).
The number of patients receiving prescriptions for
non-pain-related medications also was much higher in
the PND group than in the comparison group, including
general systemic anti-infectives (45.6% vs. 34.6%, respec-
tively), ACE inhibitors (26.6% vs. 16.8%), antiulcerants
(e.g., acid pump inhibitors, H2 blockers) (23.7% vs.
12.1%), dermatologicals (23.6% vs. 17.1%), and cough
and cold preparations (21.1% vs. 16.4%) (all p < 0.01)
(Table 4). Overall use of non-pain-related medications
was substantially higher among PND patients versus
patients in the comparison group–for example, 54.4% of
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Painful neuropathic disorder Patients with painful neuropathies (N = 31,688)
Diabetic neuropathy 658 (2.1)
Diabetic neuropathy 812 (2.6)
Back pain with neuropathic involvement 14,689 (46.4)
Neck pain with neuropathic involvement 589 (1.9)
Cancer with neuropathic pain 0 (0.0)
Causalgia 73 (0.2)
Phantom limb pain 76 (0.2)
Trigeminal neuralgia 965 (3.0)
Atypical facial pain 702 (2.2)
Neuropathic pain, unspecified
Neuralgia unspecified 1,737 (5.5)
Neuralgia, neuritis and radiculitis unspecified 2 (0.0)
Neuralgia, neuritis or radiculitis NOS 3 (0.0)
Neuritis unspecified 70 (0.2)
Neuropathic pain 698 (2.2)
Peripheral neuropathy 573 (1.8)
Polyneuropathy unspecified 2 (0.0)
Any of above 3,085 (9.7)
Nerve impingement syndromes
Carpal tunnel syndrome 548 (1.7)
CTS-Carpal tunnel syndrome 3,379 (10.7)
Cubital tunnel syndrome 20 (0.1)
Median nerve compression in forearm 1 (0.0)
Meralgia paraesthetica 302 (1.0)
Morton’s metatarsalgia 98 (0.3)
Morton’s neuralgia 74 (0.2)
Nerve root and plexus compressions in 22 (0.1)
diseases EC
Tarsal tunnel syndrome 9 (0.0)
Any of above 4,453 (14.1)
Other
Acute infective polyneuritis 0 (0.0)
Acroparaesthesia-Schultze’s type 0 (0.0)
Acroparaesthesia - unspecified 0 (0.0)
Alcoholic polyneuropathy 4 (0.0)
Burning feet syndrome 31 (0.1)
C/O paraesthesia 1,999 (6.3)
Hereditary and idiopathic peripheral neuropathy 2 (0.0)
Hereditary or idiopathic peripheral neuropathy NOS 11 (0.0)
Hereditary peripheral neuropathy 2 (0.0)
Hereditary sensory neuropathy 2 (0.0)
Inflammatory and toxic neuropathy 6 (0.0)
Korsakov’s alcoholic psychosis with peripheral neuritis 0 (0.0)
Median nerve neuritis 2 (0.0)
Mononeuritis lower limb 7 (0.0)
Mononeuritis multiplex 3 (0.0)
Mononeuritis of unspecified site NOS 1 (0.0)
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Page 4 of 13the former group received prescriptions for three or
more different types of non-pain-related medications
during the study period, versus only 39.1% of the latter
group.
Patients with PNDs averaged significantly more GP
visits during the 12-month study (mean [95% CI] = 22.8
[22.6, 23.0] vs. 14.2 [14.1, 14.3] for comparison group; p
< 0.01) (Table 5). They also had approximately twice as
Table 1 Distribution of painful neuropathic disorders* (Continued)
Mononeuritis of upper limb and mononeuritis multiplex 1 (0.0)
Mononeuritis upper limb NOS 2 (0.0)
Nerve root and plexus disorders 41 (0.1)
Nerve root or plexus disorder NOS 8 (0.0)
Neuralgic amyotrophy 6 (0.0)
Neuritis ulnar nerve 9 (0.0)
Neuropathy in association with hereditary ataxia 0 (0.0)
O/E-hyperaesthesia present 20 (0.1)
O/E-paraesthesia in hands 25 (0.1)
O/E-paraesthesia present 2 (0.0)
Other idiopathic peripheral neuropathy 2 (0.0)
Other idiopathic peripheral neuropathy NOS 0 (0.0)
Other mononeuritis lower limb 0 (0.0)
Other nerve root or plexus disorder 2 (0.0)
Other toxic agent polyneuropathy 0 (0.0)
Other toxic or inflammatory neuropathy 0 (0.0)
Other upper limb mononeuritis 1 (0.0)
Paraesthesia 0 (0.0)
Parsonage-Aldren-Turner syndrome 0 (0.0)
Peripheral neuritis in pregnancy 0 (0.0)
Peripheral neuropathy-hereditary or idiopathic 145 (0.5)
Policeman’s disease 2 (0.0)
Polyneuropathy 23 (0.1)
Polyneuropathy due to drugs 0 (0.0)
Polyneuropathy in disease NOS 1 (0.0)
Polyneuropathy in disseminated lupus erythematosus 0 (0.0)
Polyneuropathy in porphyria 0 (0.0)
Polyneuropathy in rheumatoid arthritis 0 (0.0)
Polyneuropathy in sarcoidosis 0 (0.0)
Polyneuropathy in uraemia 0 (0.0)
Polyneuropathy in vitamin B deficiency 0 (0.0)
Radiculitis unspecified 7 (0.0)
Ramsey-Hunt syndrome 18 (0.1)
Toxic or inflammatory neuropathy NOS 0 (0.0)
Ulnar neuritis 139 (0.4)
Unspecified mononeuritis lower limb 0 (0.0)
D paraesthesia 1,756 (5.5)
X Polyneuropathy, unspecified 1 (0.0)
X Inflammatory polyneuropathy, unspecified 0 (0.0)
Any of above 4,281 (13.5)
Any of above 31,688 (100.0)
*All values are number of patients (%).
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18-44 8,621 (27.2) 8,621 (27.2)
45-54 6,056 (19.1) 6,056 (19.1)
55-64 6,577 (20.8) 6,577 (20.8)
≥ 65 10,434 (32.9) 10,434 (32.9)
Mean (SD) 56.1 (16.6) 56.1 (16.6) —
Sex —
Males 12,178 (38.4) 12,178 (38.4)
Females 19,510 (61.6) 19,510 (61.6)
Comorbidities
Infectious and parasitic diseases 5,822 (18.4) 3,308 (10.4) <0.01
Neoplasms 1,787 (5.6) 1,281 (4.0) <0.01
Any endocrine, nutritional and metabolic diseases, and
immunity disorders
10,699 (33.8) 7,604 (24.0) <0.01
Diseases of the blood and blood-forming organs 2,487 (7.8) 1,507 (4.8) <0.01
Any anxiety 897 (2.8) 547 (1.7) <0.01
Any depression 1,365 (4.3) 827 (2.6) <0.01
Any disease of the nervous system and sense organs 14,691 (46.4) 5,854 (18.5) <0.01
Any disease of the circulatory system 9,071 (28.6) 6,837 (21.6) <0.01
Any disease of the respiratory system 10,485 (33.1) 7,786 (24.6) <0.01
Any disease of the digestive system 9,970 (31.5) 5,488 (17.3) <0.01
Any disease of the genitourinary system 5,019 (15.8) 3,497 (11.0) <0.01
Complications of pregnancy, childbirth, and the
puerperium
325 (1.0) 241 (0.8) <0.01
Any disease of the skin and subcutaneous tissue 9,773 (30.8) 7,136 (22.5) <0.01
Diseases of the musculoskeletal system and connective
tissue
Back pain 15,444 (48.7) 693 (2.2) <0.01
Cervical pain 2,011 (6.3) 615 (1.9) <0.01
Arthritis 2,116 (6.7) 1,203 (3.8) <0.01
Fibromyalgia 76 (0.2) 11 (0.0) <0.01
Other body/joint pain 10,481 (33.1) 3,832 (12.1) <0.01
Other 1,993 (6.3) 917 (2.9) <0.01
Any disease of the musculoskeletal system and
connective tissue
23,529 (74.3) 6,233 (19.7) <0.01
Congenital anomalies 81 (0.3) 44 (0.1) <0.01
Symptoms, signs, and ill- defined conditions
Fatigue 16 (0.1) 12 (0.0) 0.45
Headache 392 (1.2) 79 (0.2) <0.01
Chest pain 387 (1.2) 216 (0.7) <0.01
Abdominal pain 640 (2.0) 351 (1.1) <0.01
Anxiety-related symptoms 0 (0.0) 0 (0.0) —
Gastric-related symptoms 3 (0.0) 1 (0.0) 0.32
Other 6,420 (20.3) 2,989 (9.4) <0.01
Any symptoms, signs, and ill- 7,320 (23.1) 3,507 (11.1) <0.01
defined conditions
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1.4]) and hospitalizations (0.2 [0.2, 0.2] vs. 0.1 [0.1, 0.1])
(both p < 0.01). A total of 16.5% of PND patients had
one or more “sick notes” (i.e., physician-excused work
absences) during the year, versus 7.0%, of the compari-
son group.
Discussion
Over a 12-month period, patients with PNDs were
approximately twice as likely to have been prescribed
pain-related medications by their GPs than patients
without evidence of these disorders (83% vs. 43%,
respectively)-most commonly, NSAIDs and opioids.
Despite the proven efficacy of antidepressants (espe-
cially, TCAs) in treating neuropathic pain, which has led
to recommendations regarding their use as first-line
therapy [4-6,36,37], only 30% of PND patients received
prescriptions for these agents, and only 12% had been
prescribed AEDs. These patterns of medication prescrib-
ing may indicate that UK GPs may be more comfortable
with “traditional” analgesics for the treatment of neuro-
pathic pain, which may have been appropriate to some
degree, given that evidence of efficacy of opioids in neu-
ropathic pain was available during the study period
[37-41]. (We also note that current treatment recom-
mendations, which were promulgated after the end of
our study period, list opioids as second- and/or third-
line options for neuropathic pain [5,6].) On the other
h a n d ,w ew e r eu n a b l et oa s c e r t a i nt h en u m b e ro f
patients who received TCAs and AEDs in the past and
discontinued these medications due to adverse effects or
lack of efficacy. We also note that back pain with neuro-
pathic involvement-the most frequently noted PND
(~46% of all PND patients)-is often associated with both
neuropathic and nociceptive pain; the latter often
responds well to NSAIDs and/or opioids.
Patients with PNDs also had more GP encounters
with diagnoses of other medical problems (e.g., digestive,
circulatory, and respiratory disorders, depression,
anxiety) compared with their age-and sex-matched peers
without evidence of PND; they also had higher levels of
use of non-pain-related medications, such as anti-ulcer-
ants, systemic anti-infectives, and dermatologicals.
Patients with PNDs averaged 10 additional GP office vis-
its over 1 year, and twice as many specialist referrals and
hospitalizations; 17% had at least one physician-excused
absence from work versus as opposed to only 7.0% in
the comparison group. Other studies of US and German
patients have reported similar findings [7,8].
While the precise reasons for these associations are
u n c l e a r ,an u m b e ro fp o s s i b l ee x p l a n a t i o n sc o m et o
mind. For one, some comorbid conditions may be etio-
logically related to PNDs-for example, diabetes, vascular
complications thereof, and diabetic peripheral neuropa-
thy-and such associations therefore are not unexpected.
More generally, since neuropathic disorders are often
chronic and difficult to treat, patients with PNDs may
present more frequently to their GPs than patients with-
out these disorders. More frequent visits may lead to
more opportunistic case findings, and hence a higher
rate of clinical recognition of many complaints and dis-
eases that otherwise might have gone undiagnosed and/
or untreated. Difficulties in diagnosing neuropathic dis-
orders also may have yielded spuriously high rates of
comorbid conditions among PND patients. On the other
hand, since THIN does not have a direct link to hospital
data and/or sick notes, our findings may actually under-
estimate the prevalence of various comorbidities.
Further study is needed to better understand how com-
mon these comorbidities are in patients with PNDs, as
well as the relationship between these conditions and
PNDs.
In their study utilizing another electronic database
containing information from GP encounters in the UK,
Gore and colleagues reported that NSAIDs were the
most commonly dispensed medication among patients
with “pure” PNDs (i.e., conditions in which pain was
believed to be predominantly neuropathic in nature)
Table 2 Demographic and clinical characteristics of study subjects* (Continued)
Any injury and poisoning 2,991 (9.4) 2,021 (6.4) <0.01
Any sleep disorder 528 (1.7) 257 (0.8) <0.01
Any of above** 31,447 (99.2) 24,768 (78.2) <0.01
Number of comorbidities** <0.01
0 241 (0.8) 6,920 (21.8)
1 3,632 (11.5) 6,757 (21.3)
2 4,617 (14.6) 5,648 (17.8)
3 4,883 (15.4) 4,222 (13.3)
≥ 4 18,315 (57.8) 8,141 (25.7)
*Unless otherwise indicated, all values are number (%).
**Excluding painful neuropathic disorders.
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received TCAs, 12% received AEDs, 11% received a sec-
ond-generation antidepressants (e.g., SSRIs), and 9%
received opioids. We generally observed much higher
levels of prescribing of these medications in our study,
the only exception being NSAIDs. Of particular note,
the number of PND patients who were prescribed
opioids was almost fivefold higher in our study than
that reported by Gore and colleagues. While the precise
reasons for this difference are unclear, it may be due to
differences in operational definitions of study measures
(e.g., how combination products containing NSAIDs and
opioids were classified) and/or differences in the study
databases. Another possible reason may be changes in
Table 3 Use of pain-related medications among study subjects*






Antiepileptic drugs 3,838 (12.1) 283 (0.9) <0.01
Benzodiazepines 4,127 (13.0) 1,546 (4.9) <0.01
Corticosteroids 3,297 (10.4) 1,563 (4.9) <0.01
Nonsteroidal anti- inflammatory drugs
Cyclooxygenase-2 inhibitors 730 (2.3) 209 (0.7) <0.01
Other nonsteroidal anti- inflammatory
drugs
17,597 (55.5) 6,946 (21.9) <0.01
Any of above 17,902 (56.5) 7,059 (22.3) <0.01
Muscle relaxants 422 (1.3) 70 (0.2) <0.01
Sedatives/hypnotics 1,548 (4.9) 749 (2.4) <0.01
Opioids
Short-acting opioids 15,587 (49.2) 4,369 (13.8) <0.01
Long-acting opioids 719 (2.3) 66 (0.2) <0.01
Any of above 15,674 (49.5) 4,388 (13.8) <0.01
Antidepressants
Tricyclic antidepressants 6,320 (19.9) 477 (1.5) <0.01
Monoamine oxidase inhibitors 12 (0.0) 7 (0.0) 0.25
Selective serotonin reuptake inhibitors 3,397 (10.7) 2,259 (7.1) <0.01
Other antidepressants 999 (3.2) 523 (1.7) <0.01
Any of above 9,463 (29.9) 3,038 (9.6) <0.01
Antimigraine
Triptans 480 (1.5) 268 (0.8) <0.01
Other antimigraine 231 (0.7) 110 (0.3) <0.01
Any of above 647 (2.0) 351 (1.1) <0.01
Miscellaneous
Injectable analgesics 759 (2.4) 410 (1.3) <0.01
Topical analgesics 4,258 (13.4) 2,502 (7.9) <0.01
Other 107 (0.3) 49 (0.2) <0.01
Any of above 4,941 (15.6) 2,896 (9.1) <0.01
Any of above 26,265 (82.9) 13,745 (43.4) <0.01
Number receiving <0.01
None of the above 5,434 (17.1) 17,952 (56.7)
1 of the above 7,877 (24.9) 8,047 (25.4)
2 of the above 7,919 (25.0) 3,677 (11.6)
3 of the above 5,264 (16.6) 1,368 (4.3)
≥ 4 of above 5,194 (16.4) 644 (2.0)
Any of above 26,265 (82.9) 13,745 (43.4) <0.01
*Unless otherwise indicated, all values are number (%).
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Page 8 of 13practice and prescribing patterns that have occurred
between the timeframes of the Gore et al. study
(CY2001) and ours (CY2006), although the magnitude
of difference seems too high to be explained by this fac-
tor alone.
Patterns of prescribing of pain-related pharmacother-
apy among our study subjects also differed substantially
from those reported by Hall and colleagues, who used
the same database to examine patterns of pharma-
cotherapy among patients with post-herpetic neuralgia
(N = 1923), trigeminal neuralgia (N = 1862), phantom
limb pain (N = 57), and painful diabetic neuropathy (N
= 1444) between May 2002 and July 2005 [11]. Specifi-
cally, Hall et al. reported substantially higher percen-
tages of patients receiving prescriptions for AEDs (32.5%
vs. 12.1% in our current study) and TCAs (41.3% vs.
19.9%); we observed higher percentages of patients
receiving prescriptions for opioids (49.5% vs. 29.1% in
Hall et al.), NSAIDs (56.5% vs. 30.6% ["non-opioid
analgesics"]), and other antidepressants (10.0% vs. 3.7%).
Table 4 Use of selected non-pain-related medications among study subjects*






General anti-infectives systemic 14,451 (45.6) 10,953 (34.6) <0.01
Cough and cold preparations 6,682 (21.1) 5,188 (16.4) <0.01
Dermatologicals 7,464 (23.6) 5,415 (17.1) <0.01
ACE inhibitors 8,421 (26.6) 5,327 (16.8) <0.01
Antiulcerants 7,525 (23.7) 3,819 (12.1) <0.01
Beta-blocking agents 6,148 (19.4) 4,446 (14.0) <0.01
Anti-asthma and COPD products 5,534 (17.5) 3,450 (10.9) <0.01
Drugs used in diabetes 4,553 (14.4) 3,996 (12.6) <0.01
Diuretics 5,081 (16.0) 4,224 (13.3) <0.01
Plain antispasmodics and anticholinergics 6,267 (19.8) 4,133 (13.0) <0.01
Thyroid therapy 3,909 (12.3) 3,494 (11.0) <0.01
Calcium antagonists 4,340 (13.7) 3,565 (11.3) <0.01
Statins 4,377 (13.8) 1,900 (6.0) <0.01
Antidiarrhoeals, oral electrolyte replacers and intestinal
anti-inflammatories
3,336 (10.5) 2,116 (6.7) <0.01
Non-narcotics and anti-pyretics 2,711 (8.6) 1,802 (5.7) <0.01
Respiratory system and nasal preparations 2,558 (8.1) 1,722 (5.4) <0.01
Angiotensin-II antagonists 2,532 (8.0) 1,764 (5.6) <0.01
Heparins 2,412 (7.6) 1,573 (5.0) <0.01
Ophthalmologicals 2,158 (6.8) 1,581 (5.0) <0.01
Urologicals 2,614 (8.2) 1,406 (4.4) <0.01
Systemic antihistamines 2,313 (7.3) 1,797 (5.7) <0.01
Anti-gout preparations 2,305 (7.3) 1,531 (4.8) <0.01
Nitrites and nitrates 2,016 (6.4) 991 (3.1) <0.01
Mineral supplements 2,173 (6.9) 1,393 (4.4) <0.01
Diagnostic agents 2,201 (6.9) 1,090 (3.4) <0.01
Number receiving <0.01
None of the above 5,114 (16.1) 8,329 (26.3)
1 of the above 5,020 (15.8) 6,513 (20.6)
2 of the above 4,329 (13.7) 4,460 (14.1)
3 of the above 3,612 (11.4) 3,415 (10.8)
≥ 4 of above 13,613 (43.0) 8,971 (28.3)
Any of above 26,574 (83.9) 23,359 (73.7) <0.01
*Unless otherwise indicated, all values are number (%)
ACE: Angiotensin-converting enzyme; COPD: Chronic obstructive pulmonary disease
Berger et al. BMC Neurology 2012, 12:8
http://www.biomedcentral.com/1471-2377/12/8
Page 9 of 13The biggest reason for this discrepancy is likely the sam-
ple selected-namely, Hall et al. focused on only four
PNDs, while we included several other types of PNDs
(e.g., back pain with neuropathic involvement, causalgia,
nerve impingement syndromes).
Our study has several limitations. Perhaps most
important, our findings are based on information from
CY2006. Treatment guidelines changed after CY2006
and now recommend a number of different medications
as first-line therapy for PNDs (e.g., TCAs, selected
AEDs, selected SNRIs, topical lidocaine) [5,6]; the degree
to which our findings represent current practice pat-
terns in the UK is unknown.
Second, information on medication use was limited to
drugs prescribed by GPs. Thus, to the extent that
patients with PNDs (or those in the comparison group,
Table 5 Numbers of office visits, referrals, hospitalizations, and sick notes among study subjects*
Patients with painful neuropathies (N = 31,688) Comparison group (N = 31,688) P-Value
Number of office visits <0.01
0-5 3,314 (10.5) 9,680 (30.5)
6-10 4,489 (14.2) 5,892 (18.6)
11-15 4,602 (14.5) 4,641 (14.6)
16-20 4,295 (13.6) 3,696 (11.7)
> 20 14,988 (47.3) 7,779 (24.5)
Mean (95% CI) 22.8 (22.6-23.0) 14.2 (14.1-14.3) <0.01
Median (IQR) 19 (11) 11 (4)
Minimum 1 1
Maximum 356 362
Number of referrals <0.01
0 11,136 (35.1) 17,875 (56.4)
1 5,751 (18.1) 5,256 (16.6)
2 3,664 (11.6) 2,641 (8.3)
≥ 3 11,137 (35.1) 5,916 (18.7)
Mean (95% CI) 2.8 (2.8-2.9) 1.4 (1.4-1.4) <0.01
Median (IQR) 1.0 (0.0-4.0) 0.0 (0.0-2.0)
Minimum 0 0
Maximum 55 65
Number of hospitalizations <0.01
0 28,538 (90.1) 29,971 (94.6)
1 2,124 (6.7) 1,175 (3.7)
2 635 (2.0) 352 (1.1)
≥ 3 391 (1.2) 190 (0.6)
Mean (95% CI) 0.2 (0.2-0.2) 0.1 (0.1-0.1) <0.01
Median (IQR) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
Minimum 0 0
Maximum 23 38
Number of sick notes <0.01
0 26,453 (83.5) 29,474 (93.0)
1 2,046 (6.5) 1,111 (3.5)
2 1,109 (3.5) 505 (1.6)
≥ 3 2,080 (6.6) 598 (1.9)
Mean (95% CI) 0.5 (0.4-0.5) 0.2 (0.1-0.2) <0.01
Median (IQR) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
Minimum 0 0
Maximum 19 19
*Unless otherwise indicated, all values are number (%).
CI confidence interval; IQR interquartile range
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Page 10 of 13for that matter) used medications available for direct
retail purchase (i.e., without a prescription) and/or
received “private prescriptions” (i.e., prescriptions wholly
paid for by the patient [as opposed to the NHS), we
may have underestimated total medication use.
Third, we do not know the reason(s) why particular
medications were prescribed (e.g., for the treatment of
PNDs or for pain associated with other conditions).
Since some medications designated as “pain-related”
also may be used to treat conditions that are not typi-
cally associated with pain (e.g., AEDs and seizure disor-
ders, antidepressants and depression), it would be
incorrect to infer that these agents were used exclusively
for the treatment of neuropathic pain. However, only
4% of PND patients-and 3% of those in the comparison
group-had any encounters at which a diagnosis of
depression was recorded; corresponding values for epi-
lepsy were 0.2% and 0.1%, respectively (data not shown).
Similarly, given the widespread prevalence of comorbid
pain-related conditions among patients with PNDs, as
well as the possibility of “mixed” pain (i.e., neuropathic
and nociceptive) among those with back pain with neu-
ropathic involvement, it is possible that NSAIDs (and
other pain-related medications for that matter) may
have been prescribed for the treatment of pain that was
not neuropathic in origin (e.g., triptans for migraine
headache). Since we did not have access to medical
records, the degree to which this actually occurred must
remain conjectural.
Fourth, the study database is limited to information
from GP encounters. Given the large numbers of PND
patients with medical and psychiatric comorbidities-as
well as the difficulty of treating PNDs-it is reasonable to
expect that some patients in the study sample also had
encounters with healthcare providers other than GPs.
Fifth, the GP-centric records of referrals, sick notes,
and hospitalizations that are available in the study data-
base are complete only to the extent that GPs actually





Diabetic neuropathy 250 AT, 250 F, C106.00, C106.11, C106.12, C106.13, C106000, C106100, C106y00, C106z00, C108200, C108211,
C108212, C108B00, C108B11, C108B12, C108C00, C108C11, C108C12, C108J00, C108J11, C108J12, C109200, C109211,
C109212, C109A00, C109A11, C109A12,C109B00, C109B11, C109B12, C10A400, C10E200, C10E211, C10E212, C10F200,
C10F211, C10FH00, C10FH11, F345000, F35z000, F372.00, F372.11, F372.12, F372000, F372100, F381311, F3y0.00
Post-herpetic neuralgia 054 G, 355 PH, A531.11, A531200, A531300, A531500, A531511, F300.00, F374400
Back pain with neuropathic
involvement
352, 7286, 3499E, 353 A, 353 C, 353 HP, 353 NP, 353 NT, 353 PP, 353 T, 355 AR, 355 AT, 7251D, 7285A, 7288LM,
7288RP, 7289B, 7289CE, F161400, F163.00, F163000, F163200, F163z00, F16y.00, F16y000, F16y100, F16yz00, F16z.00,
F16z.11, F16z.12, F246.00, F246000, F246100, F246z00, F29y400, F29y411, F337100, F337200, F337200, F337300,
F350.00, F378.00, N113.00, N113000, N113100, N113200, N115.00, N115000, N115100, N115200, N11B.00, N11B000,
N11B100, N11B200, N11C.00, N11C000, N11C100, N11C200, N11y200, N11z100, N129.00, N129.11, N129000,
N129200, N129300, N129z00, N12B.00, N12B100, N12B200, N12C400, N134.11, N142000, N143.00, N143.11, N144.00,
N144.00, N144000, N144100, N144z00, N144z00, Nyu6200, Nyu6300, Nyu7300, Nyu7400
Neck pain with neuropathic
involvement
7284, 3470 CE, 352 CS, 355 AS, 357 J, F330300, N111.00, N111000, N111100, N111200, N111300, N119.00, N119000,
N119100, N119200, N129100, N12B000, N12zH00, N134.00, N134.12, N134.12
Cancer with neuropathic pain F337000, F373.00, Fyu7400
Causalgia 355 CL, F344.00, N337.12, N337111
Phantom limb pain 7816PL, 7816PM, 7816PN, F336.00, F336000
Trigeminal neuralgia 1475.00, 7021400, 7023000, 7024400, 7024411, 7025400, 7027400, 7028400, 7028511, 351 A, 355 JW, 357 H, F301.00,
F301000, F301z00, Fyu6000
Atypical facial pain 351 AF, 351 BA, F302.00, F321.00
Other painful neuropathies 1B46.00, 261 BR, 276 NR, 29B4.00, 29B5.00, 29B5000, 3479DT, 351 OC, 7871 HA, 7871 HB, 792 N, 792 PN, A531111,
A72x100, C262300, C34y400, F335.00, F335.11, F342.11, F342000, F370100, F370z00, FyuAE00, G73y400, G73y411,
G73y500, G73y511, G73y600, R020700, 340.12, 352, 355.00, 357, 7283, 7288, 3032R, 3039PN, 3499M, 352 L, 352 LN,
354 P, 355 A, 355 AB, 355 AQ, 355 AV, 355 B, 355 C, 355D, 357 C, 357 K, 357 KL, 357 KP, 357 LN, 357 ME, 357 NL,
357TT, 7283BR, 7284RP, 984 N, 9851N, 9909ML, ‘E011100, F33..00, F337.00, F33y.00, F33z.00, F34..00, F340.00, F340.12,
F341000, F341100, F345.00, F34y.00, F34z.00, F35..00, F351.00, F355.00, F356000, F356100, F356100, F35x.00, F35y.00,
F35z.00, F35z.11, F36..00, F360.00, F360z00, F362.00, F364.00, F365.00, F366.00, F367.00, F36y.00, F36yz00, F36z.00,
F37..00, F37..11, F370.00, F371.00, F371000, F371100, F371200, F371z00, F374.00, F374000, F374100, F374200,
F374300, F374500, F374600, F374700, F374800, F374900, F374A00, F374z00, F375.00, F376.00, F377.00, F37x.00,
F37y.00, F37y000, F37z.00, F37z.11, Fyu1300, Fyu6.00, Fyu6500, Fyu6A00, Fyu6B00, Fyu6C00, Fyu6D00, Fyu7.00,
Fyu7100, Fyu7200, Fyu7300, Fyu7500, Fyu7600, Fyu7700, Fyu7800, Fyu7900, Fyu7B00, Fyu7C00, FyuAC00, L164.00,
L164000, L164200, L164300, L164400, L164z00, N134.14, N1y0.00, N1y0.00, N242.00, N242000, N242100, N242200,
N242300, N242z00, N242z11
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Page 11 of 13record such information; to the extent that this informa-
tion is not recorded by GPs, our findings may represent
underestimates of healthcare utilization and prescribing
patterns in this population.
Sixth, study subjects were selected based on evidence
of at least one GP encounter during which a diagnosis
of a PND was recorded during the one-year study per-
iod. Thus, patients who were exclusively under the care
of specialists (e.g., neurologists, pain specialists) for their
neuropathic pain, but who saw GPs for other reasons,
would not necessarily have had GP encounters at which
PNDs were noted. Not only would these patients not
have been designated as having PNDs, but they also
could have been selected for inclusion in the compari-
son group. On the other hand, the database does not
contain information on how physicians rendered their
diagnoses. Given that some types of PNDs are more dif-
ficult to diagnosis than others [42-44], and others are
not exclusively neuropathic in origin (e.g., atypical facial
pain) [45], it is possible that we may have misclassified
some patients as having PNDs who in fact suffered from
nociceptive pain. Unfortunately, since the database does
not contain information that would shed light on these
issues, the nature and extent of any misclassification
that might have occurred is unknown.
Conclusions
Patients with PNDs under the care of GPs in the UK
have relatively high levels of use of healthcare services
and pain-related (and other) pharmacotherapy. Because
treatment guidelines evolved while our study was under-
way, it is unknown whether patterns of pharmacother-
apy that we observed are representative of clinical
practice in the UK today.
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